Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
15 sept. 2021 07h00 HE
|
Pulmocide
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA Pulmocide raised $92 million in Series C funds...
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA
15 sept. 2021 02h00 HE
|
Pulmocide
Pulmocide’s lead drug candidate opelconazole (PC945) granted Orphan Drug, Fast Track and Qualified Infectious Disease Product Designations by US FDA Pulmocide raised $92 million in Series C funds...
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
27 mai 2021 07h00 HE
|
Pulmocide
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company...
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945
27 mai 2021 02h00 HE
|
Pulmocide
Pulmocide Raises $92 million in a Series C Financing to Fund Registration Program for PC945 London, UK, 27 May 2021 – Pulmocide Ltd., (“the Company”) a late-stage biopharmaceutical company...
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections
11 mars 2021 08h00 HE
|
Pulmocide
Pulmocide announces publication of clinical data in two peer-reviewed publications highlighting potential of PC945, a novel inhaled antifungal drug candidate, in lung infections Case studies...
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence
13 août 2019 07h00 HE
|
Pulmocide
Pulmocide announces Journal of Antimicrobial Chemotherapy publication of novel antifungal PC945 activity against Candida auris, a health threat gaining global prominence C.auris is often multi-drug...
Pulmocide announces Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus
02 juil. 2019 07h00 HE
|
Pulmocide
Pulmocide announces Scientific Reports (Nature Research) publication showing PC945 in combination with standard antifungal treatment causes a synergistic effect against Aspergillus fumigatus ...
Pulmocide presents clinical update from promising antifungal program at 2019 Respiratory Innovation Summit
17 mai 2019 07h00 HE
|
Pulmocide
Pulmocide presents clinical update from promising antifungal program at 2019 Respiratory Innovation Summit London, UK; 17 May 2019 – Pulmocide Ltd, which is developing first-in-class inhaled...